Pharmacokinetic Interaction Between the HCV Protease Inhibitor MK-5172 and Midazolam, Pitavastatin, and Atorvastatin in Healthy Volunteers

被引：0

作者：

Caro, Luzelena ^{[1
]}

Talaty, Jennifer E. ^{[1
]}

Guo, Zifang ^{[2
]}

Reitmann, Christina ^{[3
]}

Fraser, Iain P. ^{[3
]}

Evers, Raymond ^{[4
]}

Swearingen, Dennis ^{[5
]}

Yeh, Wendy W. ^{[3
]}

Butterton, Joan R. ^{[3
]}

机构：

[1] Merck & Co Inc, Clin Drug Metab & Pharmacokinet, Whitehouse Stn, NJ USA

[2] Merck & Co Inc, Early Clin Dev Stat, Whitehouse Stn, NJ USA

[3] Merck & Co Inc, Clin Res, Whitehouse Stn, NJ USA

[4] Merck & Co Inc, Transporter In Vitro Technol, Whitehouse Stn, NJ USA

[5] Celerion, Tempe, AZ USA

来源：

HEPATOLOGY | 2013年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

477

引用

页码：437A / 438A

页数：2

共 50 条

[1] Pharmacokinetic Interaction Between the HCV Protease Inhibitor MK-5172 and Efavirenz in Normal Healthy Volunteers
Talaty, Jennifer E.
Caro, Luzelena
Yeh, Wendy W.
Fraser, Iain P.
Guo, Zifang
Butterfield, Kristin
Reitmann, Christina
Dunnington, Katherine M.
DeGroot, Bruce J.
Youngberg, Stephen P.
Butterton, Joan R.
HEPATOLOGY, 2013, 58 : 445A - 445A
[2] Pharmacokinetic Interaction Between the HCV Protease Inhibitor MK-5172 and IV and Oral Rifampin in Healthy Volunteers
Caro, Luzelena
Talaty, Jennifer E.
Guo, Zifang
Butterfield, Kristin
Prueksaritanont, Thomayant
Rasmussen, Scott
Fraser, Iain P.
Yeh, Wendy W.
Butterton, Joan R.
HEPATOLOGY, 2013, 58 : 446A - 447A
[3] No Pharmacokinetic Interaction Between HCV Protease Inhibitor MK-5172 and HCV NS5A Inhibitor MK-8742 in Healthy Volunteers
Yeh, Wendy W.
Caro, Luzelena
Huang, Xiaobi
Mangin, Eric
Jumes, Patricia
Rasmussen, Scott
Butterton, Joan R.
HEPATOLOGY, 2013, 58 : 438A - 438A
[4] Lack of Pharmacokinetic Interaction Between HCV Protease Inhibitor MK-5172 and HCV NS5A Inhibitor Daclatasvir in Healthy Volunteers
Yeh, Wendy W.
Fraser, Iain P.
Bifano, Marc
Caro, Luzelena
Talaty, Jennifer E.
Guo, Zifang
McCarthy, Jennifer M.
Youngberg, Stephen P.
Butterton, Joan R.
HEPATOLOGY, 2013, 58 : 430A - 431A
[5] Pharmacokinetic Interactions Between the HCV Protease Inhibitor MK-5172 and Ritonavir-Boosted HIV Protease Inhibitors (Atazanavir, Lopinavir, Darunavir) in Healthy Volunteers
Caro, Luzelena
Talaty, Jennifer E.
Guo, Zifang
Fraser, Iain P.
Davis, Henry U.
O'Reilly, Terry
Yeh, Wendy W.
Butterton, Joan R.
HEPATOLOGY, 2013, 58 : 442A - 443A
[6] Pharmacokinetic Interaction Between the HCV Protease Inhibitor Boceprevir and Prednisone in Healthy Volunteers
Jumes, Patricia
Feng, Hwa Ping
Chatterjee, Manash
Xuan, Fengjuan
Connolly, Sandra M.
Wagner, John A.
Butterton, Joan R.
HEPATOLOGY, 2012, 56 : 1076A - 1076A
[7] NO EVIDENCE OF PHARMACOKINETIC DRUG-DRUG INTERACTION IN HEALTHY SUBJECTS BETWEEN COADMINISTERED GRAZOPREVIR (MK-5172)/ELBASVIR (MK-8742) AND SOFOSBUVIR
Marshall, W. L.
Yeh, W. W.
Stypinski, D.
Auger, P.
Bethel-Brown, C.
Caro, L.
Jumes, P.
Huang, X.
Guo, Z.
Martinho, M.
Feng, H-P
Armas, D.
Brejda, J.
Iwamoto, M.
Butterton, J. R.
JOURNAL OF HEPATOLOGY, 2015, 62 : S686 - S686
[8] A PHASE 1 STUDY TO EVALUATE THE INTERACTION OF HCV NS5B INHIBITOR MK-3682 WITH HCV NS3/4A PROTEASE INHIBITOR MK-5172 AND HCV NS5A INHIBITOR MK-8408 IN HEALTHY SUBJECTS
Zhou, X. -J.
Sicard, E.
Chen, J.
Frank, D.
Gao, W.
Rizk, M. L.
Rhee, E. G.
Butterton, J. R.
Sullivan-Bolyai, J.
JOURNAL OF HEPATOLOGY, 2015, 62 : S646 - S646
[9] Development of a Practical, Asymmetric Synthesis of the Hepatitis C Virus Protease Inhibitor MK-5172
Kuethe, Jeffrey
Zhong, Yong-Li
Yasuda, Nobuyoshi
Beutner, Gregory
Linn, Katherine
Kim, Mary
Marcune, Benjamin
Dreher, Spencer Douglas
Humphrey, Guy
Pei, Tao
ORGANIC LETTERS, 2013, 15 (16) : 4174 - 4177
[10] A Combination Containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) Demonstrates High Barrier to Resistance in HCV Replicons
Lahser, Frederick
Liu, Rong
Bystol, Karin
Xia, Ellen
Raubertas, Richard
Asante-Appiah, Ernest
Howe, Anita Y.
HEPATOLOGY, 2012, 56 : 236A - 236A

← 1 2 3 4 5 →